Financials Ultragenyx Pharmaceutical Inc.

Equities

RARE

US90400D1081

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
43.38 USD -1.65% Intraday chart for Ultragenyx Pharmaceutical Inc. -14.44% -9.28%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 2,467 9,158 5,732 3,248 3,926 3,632 - -
Enterprise Value (EV) 1 1,712 7,956 4,992 2,500 3,149 3,297 3,333 3,632
P/E ratio -6 x -45.1 x -12.6 x -4.58 x -5.8 x -6.71 x -8.39 x -13.3 x
Yield - - - - - - - -
Capitalization / Revenue 23.8 x 33.8 x 16.3 x 8.94 x 9.04 x 7.05 x 5.74 x 4.17 x
EV / Revenue 16.5 x 29.4 x 14.2 x 6.88 x 7.25 x 6.4 x 5.27 x 4.17 x
EV / EBITDA -4.12 x -25 x -13.5 x -3.96 x -5.8 x -6.52 x -8.44 x -81.9 x
EV / FCF -4.62 x -45.2 x -12.1 x -5.03 x -6.07 x -7.89 x -8.53 x -10.6 x
FCF Yield -21.6% -2.21% -8.25% -19.9% -16.5% -12.7% -11.7% -9.41%
Price to Book 3.78 x 7.3 x 6.32 x 9.23 x 12.8 x 3.64 x 3.18 x 4.04 x
Nbr of stocks (in thousands) 57,771 66,156 68,162 70,106 82,106 82,336 - -
Reference price 2 42.71 138.4 84.09 46.33 47.82 43.38 43.38 43.38
Announcement Date 2/13/20 2/11/21 2/10/22 2/16/23 2/15/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 103.7 271 351.4 363.3 434.2 514.8 632.8 870.5
EBITDA 1 -415.6 -317.9 -368.5 -630.7 -543.2 -505.6 -394.9 -44.37
EBIT 1 -424.2 -330.1 -381.7 -648.9 -569.2 -495.6 -431.6 -262
Operating Margin -408.98% -121.8% -108.63% -178.6% -131.08% -96.27% -68.21% -30.1%
Earnings before Tax (EBT) 1 -399.4 -185.4 -453 -701.7 -608.5 -535.5 -463.4 -297.7
Net income 1 -402.7 -186.6 -454 -707.4 -606.6 -532.8 -454.5 -307.5
Net margin -388.31% -68.84% -129.2% -194.71% -139.7% -103.49% -71.83% -35.32%
EPS 2 -7.120 -3.070 -6.700 -10.12 -8.250 -6.461 -5.168 -3.268
Free Cash Flow 1 -370.2 -176.1 -411.8 -496.6 -519.1 -417.9 -390.8 -341.7
FCF margin -356.96% -64.98% -117.18% -136.68% -119.53% -81.17% -61.76% -39.26%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 2/13/20 2/11/21 2/10/22 2/16/23 2/15/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 81.65 83.39 79.94 89.34 90.7 103.3 100.5 108.3 98.05 127.4 116.7 126.1 129.9 142.9 126.6
EBITDA -86.61 -99.03 - -137.1 -220.4 -140.7 -148.9 -142.6 -137.9 -113.8 - - - - -
EBIT 1 -89.83 -102.6 -136.6 -141.6 -225.1 -145.6 -154.1 -148 -145.1 -122 -133.2 -124.7 -122.8 -118.7 -124.1
Operating Margin -110.02% -122.99% -170.93% -158.48% -248.14% -140.91% -153.34% -136.61% -147.98% -95.81% -114.07% -98.91% -94.52% -83.06% -98.05%
Earnings before Tax (EBT) 1 -72.82 -122.4 -151.8 -157.9 -238.8 -153.3 -163.5 -159.1 -159 -126.9 -138.6 -131.1 -127.7 -119.9 -134.2
Net income 1 -73 -122.5 -152.3 -158.2 -245.1 -151.8 -164 -159.8 -159.6 -123.2 -140 -131.3 -128.5 -124.5 -133.7
Net margin -89.41% -146.85% -190.55% -177.03% -270.23% -146.91% -163.16% -147.57% -162.82% -96.7% -119.97% -104.17% -98.94% -87.09% -105.6%
EPS 2 -1.080 -1.790 -2.190 -2.260 -3.500 -2.160 -2.330 -2.250 -2.230 -1.520 -1.757 -1.640 -1.582 -1.518 -1.510
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/2/21 2/10/22 5/5/22 7/28/22 11/2/22 2/16/23 5/4/23 8/3/23 11/2/23 2/15/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 755 1,202 740 748 777 334 298 -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -370 -176 -412 -497 -519 -418 -391 -342
ROE (net income / shareholders' equity) -63.8% -20.6% -43.7% -111% -193% -74.2% -42.7% -43.8%
ROA (Net income/ Total Assets) -43.4% -12.9% -27.7% -46.1% -40% -39.2% -35.4% -31.2%
Assets 1 927.5 1,447 1,641 1,534 1,518 1,359 1,286 984
Book Value Per Share 2 11.30 19.00 13.30 5.020 3.740 11.90 13.60 10.70
Cash Flow per Share 2 -6.100 -2.170 -4.940 -5.440 -6.460 -5.460 -4.140 -
Capex 1 24.8 43.9 73.1 116 44.3 41.5 38.5 39.1
Capex / Sales 23.94% 16.2% 20.8% 31.96% 10.19% 8.05% 6.09% 4.5%
Announcement Date 2/13/20 2/11/21 2/10/22 2/16/23 2/15/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
44.11 USD
Average target price
90.05 USD
Spread / Average Target
+104.15%
Consensus
  1. Stock Market
  2. Equities
  3. RARE Stock
  4. Financials Ultragenyx Pharmaceutical Inc.